All News

Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.

Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.

Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

Findings from the CheckMate-901 study support the use of frontline nivolumab plus gemcitabine/cisplatin in advanced urothelial carcinoma.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.